Nanomedicines and Vaccines
NANO-VAC
Novartis (Sweden)
Täby, SueciaPublicaciones en colaboración con investigadores/as de Novartis (Sweden) (3)
2023
-
Unveiling chronic spontaneous urticaria pathophysiology through systems biology
Journal of Allergy and Clinical Immunology, Vol. 151, Núm. 4, pp. 1005-1014
2018
-
Predicting Chronic Spontaneous Urticaria Symptom Return After Omalizumab Treatment Discontinuation: Exploratory Analysis
Journal of Allergy and Clinical Immunology: In Practice, Vol. 6, Núm. 4, pp. 1191-1197.e5
2016
-
Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria
Journal of Allergy and Clinical Immunology, Vol. 137, Núm. 2, pp. 474-481